Therapy Areas: Inflammatory Diseases
Trellus Health signs contract with leading global CRO and expands clinical trial offerings
22 October 2025 - Healthcare company Trellus Health plc (AIM: TRLS) announced on Wednesday that it has signed a 12-month contract with one of the world's largest Clinical Research Organisations (...
Genentech's Gazyva (obinutuzumab) receives US FDA approval to treat adults with lupus nephritis
21 October 2025 - The Lupus Foundation of America Inc reported on Monday that the US Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab), developed by biotechnology company Genentech...
AstraZeneca wins US FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
20 October 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that it has received US Food and Drug Administration (FDA) approval for Tezspire (te...
CStone announces Phase I CS2009 data at ESMO 2025
20 October 2025 - CStone Pharmaceuticals (HKEX:2616), a China-based biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
9 October 2025 - US medical device company Autonomix Medical, Inc. (NASDAQ: AMIX) announced on Thursday that it has been granted a patent from the United States Patent and Trademark Office covering sy...
Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome
8 October 2025 - Precision diagnostic tests provider Oxford BioDynamics plc (AIM: OBD) on Wednesday announced the development of a first-in-class blood test for diagnosing Chronic Fatigue Syndrome (CF...